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climbing mountains
Jim Kling
Lee Hood took to mountain
climbing naturally, while he was
growing up in rural Montana. The
technical climbing he still practises
consists generally of “going up
vertical cliff faces.” His hobby could
be an apt metaphor for a career in
biology marked by unorthodox
approaches to daunting problems.
In the 1960s, Hood became the
first biologist to seriously bridge the
gap between biology and technology,
and he has since pioneered the
automation of crucial tasks such as
protein and DNA sequencing. As he
puts it, his career has “grown up with
the biotechnology industry.”
Others consider Hood not as a
child of biotechnology, but as one of
the industry’s prime movers. “When
Lee began [automated] protein and
DNA sequencing on microscale,
those were not very popular things
for biologists to be doing. He had the
vision to realize the impact that
[these techniques] would have,” says
David Galas, president and chief
scientific officer at Darwin
Molecular, a gene-based drug
discovery company for which Hood
has consulted since its inception.
Hood’s quests also focus on
fundamental biological questions,
but he has a special fondness for
improving techniques, so that they
can in turn be used to answer more
complex questions. In the 1980s, “a
lot of biologists looked down their
nose at that sort of thing, saying,
‘that’s not science’,” Galas recalls.
But there are few detractors now.
Without Hood’s accomplishments in
automated analysis — his automated
fluorescence sequencer is the most
successful large analytical instrument
ever sold — the Human Genome
Project would probably still be at the
planning stage. “He has been very
much a visionary,” says Galas.
Hood doesn’t argue, though his
easy-going nature — striking in one
who has successfully battled, and
risen above, the disdain of his peers
— prevents him from wording it
quite so bluntly. While Hood was
studying for his PhD at Caltech in
the mid-1960s, his mentor, Bill
Dreyer, “taught me to always think
ahead of the pack, and stay geared to
the most important problems. If you
want to change science, you invent
new technology — that has the
biggest impact.”
He was introduced very early on
to the complexities of biology.
Dreyer felt that his graduate project
— to determine how the immune
system generates its huge number of
different antibodies — would be a
“Saturday afternoon thing,” Hood
claims, with a touch of exaggeration.
They’d badly underestimated the
endeavor, as it turned out. “I started
out as a protein chemist, but had to
switch mid-stream to molecular
biology and use those techniques to
finally solve the problem.”
In 1973, Hood got tenure at
Caltech, where he built a lab empire
infamous for its size — about 70
people at its peak. While there, he
contributed intellectual capital to the
formation of nine biotech companies,
including Applied Biosystems.
But eventually he began to meet
resistance to his push to develop
technology at Caltech, and in the
early 1990s he began talking to Lee
Huntsman, provost at the University
of Washington (UW), about moving
there. Huntsman had an ace up his
sleeve. Mary Gates — mother of
software mogul Bill — was an active
member of the UW board of
regents, and talked her son into
attending a brunch there. Huntsman
bent Bill Gates’ ear, and convinced
him to attend several of Lee Hood’s
visiting lectures. Gates had a long-
standing interest in biotechnology,
and Hood’s goal has always been to
bring computer science into
biotechnology, so the two were
natural allies. In 1992, a $12 million
grant from Gates helped found the
UW Molecular Biotechnology
Department, which Hood has
directed since.
The Department has been
predictably fertile, producing, among
other innovations, a new technique
for synthesizing DNA chips and
several software programs to handle
DNA sequencing. Another program
can take protein sequences
generated by mass spectrometer
analysis and search a database for the
genes that encode them.
Still looking upwards, Hood is
now gathering $100 million funding
for an independent biotechnology
institute to be based in Seattle. He
envisages computer scientists,
engineers, and molecular biologists
working side by side to solve
complex sequencing and molecular
pathway problems. Hood hopes to
attract partner companies — from
the pharmaceutical, instrument and
software industries — to help
develop and market the innovations
that result. Monsanto is already on
board to analyze the corn genome.
The task of overseeing the new
institute, due to be launched next
year, seems monumental, but Hood
sees it as just another mountain to
climb: “I’ve always liked getting to
the top of things.”
Jim Kling is a freelance science writer, based
in Bellingham, Washington, USA.
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